Lee Ainslie - Maverick Capital
Holding/activity history for Supernus Pharmaceuticals (SUPN)
| Period | Shares | % of Portfolio | Activity | % Change to Portfolio | Reported Price |
| 2023 Q3 | 0 | 0 | Sell 100.00% | 0.00 | |
| 2023 Q2 | 7,409 | 0.00 | Reduce 11.86% | 0.00 | $30.10 |
| 2023 Q1 | 8,406 | 0.01 | Add 9.01% | 0.00 | $36.28 |
| 2022 Q4 | 7,711 | 0.01 | Reduce 13.22% | 0.00 | $35.66 |
| 2022 Q3 | 8,886 | 0.01 | Buy | 0.01 | $33.87 |
| 2022 Q1 | 0 | 0 | Sell 100.00% | 0.00 | |
| 2021 Q4 | 4,000 | 0.00 | Reduce 90.47% | 0.00 | $29.25 |
| 2021 Q3 | 41,962 | 0.01 | Reduce 26.71% | 0.00 | $26.67 |
| 2021 Q2 | 57,251 | 0.02 | Buy | 0.02 | $30.79 |
| 2021 Q1 | 0 | 0 | Sell 100.00% | 0.00 | |
| 2020 Q4 | 1,711 | 0.00 | Reduce 97.41% | 0.00 | $25.13 |
| 2020 Q3 | 66,177 | 0.03 | Buy | 0.03 | $20.84 |